August 2012
-
United Therapeutics has announced that the Phase 3 INCREASE study of Tyvaso treprostinil inhalation solution for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD) met its primary endpoint, demonstrating statistically significant improvement in six-minute… Read more . . .
-
The FDA has approved Teva’s ArmonAir Digihaler fluticasone propionate DPI for the treatment of asthma in patients aged 12 and older, the company said. ArmonAir Respiclick was approved for that indication in January 2017. Three doses… Read more . . .
-
Aradigm Corporation, which filed for bankruptcy in February 2019, said that it will sell all of its assets related to Lipoquin inhaled ciprofloxacin, Apulmiq (Linhaliq) dual release inhaled ciprofloxacin, and other inhaled ciprofloxacin candidates to… Read more . . .
-
Nanopharm CEO Jag Shur has announced the addition of three new members of the company’s management team in a LinkedIn post. The new hires include two OINDP experts: Dave Farrow, who joins the company as… Read more . . .
-
Breath Therapeutics, which was acquired by Zambon in July 2019, said that it has initiated two new trials of its liposomal cyclosporine A for inhalation (L-CsA-i) for the treatment of bronchiolitis obliterans syndrome (BOS). BOSTON-3… Read more . . .
-
OINDP experts will gather once again in Palm Desert, California from April 26-30 for the 2020 edition of the Respiratory Drug Delivery (RDD) conference. As with past RDD meetings, attendees will find a scientific program… Read more . . .
-
Copley Scientific has announced the launch of a new inhaled dissolution dose collector (IDDC) system for the collection of representative samples of particles from MDIs and DPIs for dissolution testing by USP Method 2. The… Read more . . .
-
Training device and patient onboarding company Noble International, which was acquired by Aptar Pharma in October 2019, has announced the appointment of Jeffrey Miller as Director, Business Development. The company manufactures training devices that mimic… Read more . . .
-
Seurat Therapeutics has published data from studies of its intranasal IGF-1 in rat models for the treatment of migraine in the journal Brain Research. The studies were conducted at the University of Chicago, which has… Read more . . .
-
Vectura has announced the appointment of Sharon Johnson to the newly created position of Executive VP for Delivery Management “to support innovation, customer focus and growth as the company continues with its strategic development as… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.